AMGN · News · 20260824N
Product / Drug Pipeline Progress
AMGEN INC · 2026-08-24 · Importance 31 · Surprise 42 · In source text
Amgen is advancing injectable tarlatamab into Phase 3 trials, supporting its oncology pipeline. MariTide is identified as a leading growth driver in the company’s broader pipeline and obesity-drug strategy. The pipeline is being viewed alongside Amgen’s diverse portfolio and recent biosimilar launches as a counterweight to patent expirations and pricing pressure.
Key facts
- Amgen Inc. is advancing Phase 3 trials for its injectable tarlatamab treatment. source
- Amgen Inc.'s pipeline is led by MariTide (named as a promising pipeline asset). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Amgen Inc. is advancing Phase 3 trials for its injectable tarlatamab treatment. |